The modern era of drug development for A lzheimer's disease began with the proposal of
the cholinergic hypothesis of memory impairment and the 1984 research criteria for A …

Alzheimer disease (AD) drug development has a high failure rate. Drug development
decision making can be improved based on lessons learned from past trials. Improved …

The focus of drug development in Alzheimer's disease has increasingly been on earlier
disease stages, before overt dementia, when it is difficult to assess cognitive impairment …

Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the
growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug …

Alzheimer's disease (AD) clinical trials, focused on disease modifying drugs and conducted
in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach …

Introduction Drugs that prevent the onset, slow progression, or improve cognitive and
behavioral symptoms of Alzheimer's disease (AD) are needed. Methods We searched …

Background Cholinesterase inhibitors and memantine have been approved for
management of Alzheimer's disease (AD), but there has been no consensus about the …

Alzheimer's disease (AD) is a progressive and ultimately fatal condition that causes
debilitating memory loss and extensive deterioration of cognitive and functional abilities …

Background The age gap between participants in trials and patients who could benefit from
the drugs studied has been widely documented across different clinical areas. Patients with …

In order to assist physicians in the effective pharmacologic management of this challenging
population, evidence-based pharmacologic treatment algorithms for the different stages of …